Sleep Apnea Timeline: Inspire Implant

The Inspire implant (hypoglossal nerve stimulation) is for people with moderate or severe sleep apnea who could not use CPAP. A small implanted device senses breathing and gently stimulates the nerve to the tongue, moving the tongue forward with each breath during sleep.

This page is one of seven treatment-track timelines for adult obstructive sleep apnea. The sleep study, how a track is chosen and how to read the outcomes row are covered on the sleep apnea treatment timelines page. How the device works and who qualifies are described on the Inspire implant page, and recovery after surgery on the Inspire recovery page.

Who follows this track

People with moderate or severe obstructive sleep apnea who have tried CPAP and could not use it or did not benefit. The FDA allows the device for adults with an AHI of 15 to 100, a body mass index up to 40, and fewer than a quarter of breathing events of the central type (where the brain does not signal a breath), and for teenagers 13 and older with Down syndrome. Many insurance plans use narrower limits; Medicare, for example, uses a body mass index of 35 or less. A sleep endoscopy must show that the airway does not collapse in a complete circle at the level of the palate.

Before surgery (weeks 0 to 14)

• Qualifying sleep study (week 0): often the original diagnostic study, if recent.

• Consultation (weeks 2 to 8): an ENT surgeon reviews the sleep study, examines the nose and throat, and documents the CPAP trial.

• Drug-induced sleep endoscopy (DISE): under light sedation that imitates sleep, a thin scope through the nose shows where and how the airway collapses. About 1 in 5 to 1 in 4 people who could not use CPAP have the circular pattern that rules out the device.

• Insurance approval (weeks 4 to 16): prior authorization often takes several weeks and varies widely (see preauthorization).

Surgery and activation

• Surgery day: usually outpatient or one night in the hospital, through two or three small incisions (under the jaw, on the upper chest, and sometimes on the side of the chest). The two-incision method is shorter, with equivalent results.

• Weeks 1 to 4: stitches out at about 1 week; no strenuous upper-body activity for about a month while the leads heal in place. The device stays off.

• About week 4: the device is turned on in the office at a comfortable strength, and the person learns to use the handheld remote to turn it on at bedtime and off in the morning.

• Weeks 4 to 12: the strength is raised in small steps at home, often about once a week.

• About 2 months after surgery: an in-lab sleep study fine-tunes the strength and settings.

• About 6 months: a check of results, often with another sleep test.

Side effects and complications

• Discomfort from the stimulation is common in the first year (about 6 in 10 in the main trial's follow-up) and usually improves with setting changes.

• Tongue soreness or abrasion in about 1 in 4, temporary tongue weakness in about 1 in 6, and incision discomfort in about 3 in 10.

• In real-world data from more than 20,000 implants, the device was removed in 0.7 percent at 1 year and 2.7 percent at 3 years, most often for infection, and revision surgery was needed in 1.5 percent at 1 year. Lasting nerve injury is under 1 percent, and a collapsed lung from the chest lead is uncommon.

Outcomes on this track

• Breathing (AHI): in the main trial, the AHI fell from 29 to 9 at 1 year (a 68 percent drop), stayed about 10 at 18 months and was about 6 at 3 years. When the device was turned off for a week, the AHI went back to about 26, showing the effect comes from nightly use. In a large real-world registry, the AHI fell from 33 to about 10 at 1 year, and in pooled data about 4 in 10 reached an AHI under 5.

• Sleepiness: the Epworth score fell from 11.6 to 7 at 1 year; the share with a normal score rose from 33 to 78 percent by 5 years.

• Daily life: the FOSQ rose from 14.3 to 17.3 at 1 year, an improvement most people notice; the share with a normal score rose from 15 to 67 percent by 5 years.

• Success (the AHI cut at least in half and below 20): 66 percent at 1 year in the main trial, 75 percent at 5 years, and about 74 percent across studies of more than 3,000 people. Results were better when the airway collapsed front to back at the tongue, in women, and at a lower body mass index.

• Use: about 5½ to 6 hours a night at 1 year in real-world data; 8 in 10 reported nightly use at 5 years. About 8 in 10 bed partners reported soft or no snoring at 3 years.

These are averages from groups of people, not a prediction for any one person.

Check-ups and long-term care

• Visits at about 1 week, at activation, after the fine-tuning study, at 6 months, then yearly device checks. Settings are adjusted if snoring or sleepiness return or weight changes.

• The battery lasts about 8 to 12 years and is replaced through the chest incision in a shorter procedure.

• MRI scans are possible only under the device's MRI conditions, so every care team needs to know about the implant.

• Newer stimulators from other companies, including one with a single chin incision and no implanted battery, have been approved or are in trials; this timeline follows the Inspire device used most widely.